Choosing between stem cell therapy and drugs in myelofibrosis

Leukemia
Nicolaus Kröger, R A Mesa

Abstract

Optimal clinical management of patients with primary myelofibrosis and post-essential thrombocythemia/polycythemia vera myelofibrosis is a challenge, given the typically advanced age of presentation and variability of the disease course and prognosis. Current medical therapeutic options have not demonstrated an impact on the disease course, which exceeds the palliation of disease-related extramedullary hematopoiesis and alleviation of cytopenias. In contrast, allogeneic stem cell transplantation (SCT) can lead to 'cure' but is limited due to patient's age or comorbidities. Currently, in patients, who are reasonable candidates, SCT (frequently with a reduced intensity conditioning regimen) is employed for intermediate- to high-risk disease. Current pharmaco-medical therapy is used as a bridge to transplant, or instead of transplant in poor transplant candidates. Pathogenetic insights, especially the discovery of the Janus kinase (JAK)2(V617F) mutation, have ushered in a host of new potential therapeutic agents that may augment the role of medical therapy. Similarly, the boundaries of transplantation continue to alter with strategies that decrease conditioning-related toxicity, improved antimicrobial prophylaxis and decreased gra...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Dec 1, 1992·British Journal of Haematology·G J CreemersA Hagenbeek
Jan 1, 1989·British Journal of Haematology·I DokalJ M Goldman
Dec 26, 1987·Lancet·S N WickramasingheD S Gill
Oct 1, 1988·European Journal of Haematology·E Löfvenberg, A Wahlin
Nov 1, 1984·Scandinavian Journal of Haematology·A Manoharan, W R Pitney
Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
Mar 1, 1994·British Journal of Haematology·K P DallaR K Shadduck
Aug 15, 1997·Cancer·H M KvasnickaR Fischer
Sep 9, 2000·The New England Journal of Medicine·J Benbassat
Mar 23, 2001·Annals of Hematology·N Heis-Vahidi-FardH Gisslinger
Apr 25, 2001·Pathologie-biologie·M C Le Bousse-KerdilèsUNKNOWN French INSERM research network on Idiopathic Myelofibrosis
Jul 27, 2001·British Journal of Haematology·G BarosiM Marchetti
Feb 19, 2002·British Journal of Haematology·M C PettiF Mandelli
Feb 22, 2002·Journal of Medicinal Chemistry·James F CallahanNicholas J Laping
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Peter H SchaferDavid I Stirling
Jun 20, 2003·Bone Marrow Transplantation·A DalyT Kiss
Aug 16, 2003·Blood·H Joachim DeegFrederick R Appelbaum

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hematologic Malignancy Reports·Haefaa Alchalby, Nicolaus Kröger
Feb 24, 2010·International Journal of Hematology·Alessandro Rambaldi
Jul 26, 2012·Blood Cancer Journal·K Ballen
Feb 16, 2010·Bone Marrow Transplantation·W A StewartUNKNOWN British Society for Blood and Marrow Transplantation
Feb 2, 2011·Nature Reviews. Drug Discovery·Alfonso Quintás-CardamaSrdan Verstovsek
Oct 25, 2008·Annual Review of Medicine·Omar I Abdel-Wahab, Ross L Levine
Dec 17, 2008·Hematology·Alessandro RambaldiGiovanni Barosi
Dec 5, 2008·Leukemia & Lymphoma·Ayalew Tefferi
Jun 10, 2009·Expert Opinion on Drug Safety·Ulrike BacherAxel Rolf Zander
Apr 28, 2011·Expert Opinion on Investigational Drugs·Alfonso Quintás-Cardama, Srdan Verstovsek
Jun 16, 2009·Journal of Cellular and Molecular Medicine·Alessandro M VannucchiTiziano Barbui
Mar 6, 2012·American Journal of Hematology·Melissa R DeLarioLakshmi Venkateswaran
Oct 6, 2010·Cancer·Meetu AgrawalAlfonso Quintas-Cardama
Aug 17, 2010·Clinical Lymphoma, Myeloma & Leukemia·Sameer A ParikhSrdan Verstovsek
Nov 3, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karen K BallenMukta Arora
Sep 17, 2011·Blood·Paola GuglielmelliAlessandro M Vannucchi
Jan 25, 2014·Blood·Paola GuglielmelliUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators
Mar 15, 2015·Nuclear Medicine and Molecular Imaging·Thorsten Derlin, Till Sebastian Clauditz
Jan 21, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Thorsten DerlinNicolaus Kröger
Dec 29, 2016·Blood·Alessandro M Vannucchi, Claire N Harrison
Feb 13, 2015·Clinical Nuclear Medicine·Thorsten DerlinNicolaus Kröger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.